1 Min Read
May 16 (Reuters) - Viveve Medical Inc:
* VIVEVE MEDICAL INC - ANTICIPATE SUBMITTING 30-DAY SAFETY DATA FROM FIRST 25 TREATED PATIENTS FOR VIVEVE II STUDY TO FDA FOR REVIEW BY END OF Q2 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.